Covid India Updates | Is it normal to have a blood clot after getting vaccinated? Know the truth

Due to Covid-19, the entire World is undergoing a crisis and children of every age are also not left untouched.  They are feeling more stressed or anxious in this Covid-19 era. Their daily routine is disrupted which is leading to abnormal behavioral changes. Parents need to keep a close watch on their children & check for these symptoms like excessive worry, restlessness, fatigue, difficulty in concentrating, trouble in sleeping, addiction of Social Media/web series/online games. Also, you need to know that signs of stress and anxiety can look different in every child especially depending upon their age.

Read full story here

A team of scientists has identified how and why some Covid-19 patients can develop life-threatening blood clots. The study, led by researchers at the Royal College of Surgeons in Ireland (RCSI), found the balance between a molecule that causes clotting called the von Willebrand Factor (VWF) and its regulator, ADAMTS13, is severely disrupted in Covid patients who had elevated levels of the VWF protein.

Read Here

The Russia's Covid-19 vaccine has claimed that Sputnik V is more efficient against the Delta variant of coronavirus than any other vaccine. Sputnik-V has claimed that the Gamaleya Center study has the vaccine the most effective against the Delta varriant, the one which was found in India. 

The Sputnik V vaccine was accorded emergency use authorization by the Drugs Controller General of India, joining Covishield and the indigenous Covaxin in the battle against COVID-19. The first dose of the imported vaccine was administered in Hyderabad last month. The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose.

Read the full story

Delhi reported 228 new coronavirus cases on Tuesday. With this, the tally of COVID-19 cases in the national capital has reached over 14.31 lakh, while the death toll mounted to 24,851. As many as 12 fatalities have been recorded in the last 24 hours, according to the latest bulletin issued by the Delhi health department. The COVID-19 positivity rate in the national capital stood at 0.32 percent.

The fresh infections and positivity rate have seen a slight increase from the previous day's figures. The national capital had recorded 131 COVID-19 cases, the lowest since February 22, and 16 fatalities on Monday, while the positivity rate dropped to 0.22 per cent, according to a health department bulletin.

According to a health bulletin issued by the Delhi government, 71,291 COVID-19 tests were conducted in the last 24 hours.

Two doses of Pfizer and AstraZeneca's Covid-19 vaccines are highly effective against hospitalisation from the Delta (B16172) variant, according to new analysis from Public Health England (PHE). The analysis suggests that the Pfizer-BioNTech vaccine is 96 per cent effective against hospitalisation after two doses, while the Oxford-AstraZeneca vaccine is 92 per cent effective against hospitalisation after two doses.

These are comparable with vaccine effectiveness against hospitalisation from the Alpha (B117) variant: 96 per cent after two doses with Pfizer vaccine and 92 per cent after two doses from AstraZeneca vaccines.

The new analysis included 14,019 cases of the Delta variant, 166 of whom were hospitalised between 12 April and 4 June, looking at emergency hospital admissions in England. The results have been posted as a preprint. Preprints are yet to be peer-reviewed.

-- IANS

Sharing an update about the vaccination drive in the country, the  Ministry of Health on Wednesday informed that so far, over 26 crore vaciinaes have been administered. 

The recruitment for the clinical trial Bharat Biotech's vaccine Covaxin, among children in the age group of 6-12 years will begin at the AIIMS today.  This will be followed by the clinical trial of children in the age-group of 2-6 years.

The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years. In the trial, the vaccine will be given by the intramuscular route in two doses on day 0 and day 28. These trials will take place across 525 centres.

For more details click here

India on Tuesday recorded 60,471 new cases of the novel coronavirus, along with 2,726 deaths due to the infection. According to the data shared by the Union Health Ministry, the country saw a total of 1,17,525 discharges in the last 24 hours, taking the total recovery to 2,82,80,472. The total cases of COVID-19 in India have now mounted to 2,95,70,881 with 9,13,378 active cases, the data showed. The total death toll in the country is now at 3,77,031. A total of 25,90,44,072 people have so far been vaccinated against COVID-19 in India.

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16.

READ MORE

AstraZeneca's Covid-19 vaccine remains authorised for all populations, European Medicines Agency (EMA) has said. The clarification camme after Italian newspaper La Stampa earlier quoted Marco Cavaleri, head of the EMA's vaccine strategy, recommending a stop to administration of AstraZeneca's Covid shots in Europe to people aged over 60 and younger age groups, amid fears over very rare blood clotting.

"Misinformation is making the rounds today. This is the situation: Benefit/risk balance of AstraZeneca #Covid19 vaccine is positive and it remains authorised for all populations," the EMA said in a tweet on Sunday.

Cavaleri was also quoted by the newspaper advising the use of the Johnson & Johnson vaccine preferentially for the over-60s.

READ MORE

There have been social media posts going viral trhat after getting vaccinated, it is common to get blood clots. However, in the research done in India, it is found that such incidences of blood clotting are almost negligible here.

Research is taking place in India, US and several other countries to see if booster dose will be needed for maintaining longer efficacy of COVID-19 vaccines, a senior doctor has said.

"It is about five months since the start of vaccination in India. Everyone is looking towards the government, doctors and scientists if they are safe or they need a booster dose to make themselves safe. This is the important question and we are having lots of research in India and abroad including US and European countries," Dr Sanjeev Sinha, Professor in Department of Medicine at AIIMS Delhi said.

"We will have other data also in two-three months. Then we will be able to decide on booster dose. Everything will be based on research. There is some work is going on booster dose at AIIMS also," he added.

READ MORE

A single dose of vaccine is sufficient for those already infected by Covid-19, revealed a study by Hyderabad's AIG Hospitals.

The hospital announced on Monday that it conducted a study on 260 healthcare workers who got vaccinated between January 16 and February 5 to assess the immunological memory response in all those patients. All patients were given the Covishield vaccine.

Two significant observations came out of the study, which has been published in the International Journal of Infectious Diseases, a peer-reviewed journal.

The previously infected group (people who got infected with Covid-19) showed a greater antibody response to a single dose of vaccine compared with those who had no prior infection.

READ MORE